A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
NCT ID: NCT07254806
Last Updated: 2026-02-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE3
Total Enrollment
162 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-12-23
Study Completion Date
2028-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks).
The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening.
Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham.
Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date.
Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio.
* IDCT (n=108)
* Sham (n=54)
The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening.
Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham.
Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date.
Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio.
* IDCT (n=108)
* Sham (n=54)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration
NCT03347708
Degenerative Disc Disease
COMPLETED
PHASE1
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration
NCT03955315
Degenerative Disc Disease
COMPLETED
PHASE1
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992
Lumbar Degenerative Disc Disease
ACTIVE_NOT_RECRUITING
PHASE3
Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis
NCT01052571
Low Back Pain
COMPLETED
NA
Adipose Cells for Degenerative Disc Disease
NCT02097862
Degenerative Disc Disease
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Adult subjects with a diagnosis of single-level, mild to moderate, symptomatic lumbar (L3-S1) intervertebral disc degeneration that give consent and meet all the inclusion criteria and none of the exclusion criteria will be enrolled in this study. The disease, single-level disc will be known as the 'target disc' and will be either L3/L4, L4/L5, or L5/S1.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Degenerative Disc Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
All parties in this trial will be blinded with the exception of the unblinded injecting sub-investigator and their team.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IDCT (n=108); Intradiscal injection of IDCT in a single target disc
1 mL intradiscal injection of 9,000,000 cells/mL
Group Type
EXPERIMENTAL
IDCT (rebonuputemcel)
Intervention Type
BIOLOGICAL
Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.
Sham (n=54);
Needle insertion up to the annulus of a single target disc.
Group Type
SHAM_COMPARATOR
Sham (No Treatment)
Intervention Type
OTHER
Single Sham needle insertion up to the annulus of a single target disc.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IDCT (rebonuputemcel)
Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.
Intervention Type
BIOLOGICAL
Sham (No Treatment)
Single Sham needle insertion up to the annulus of a single target disc.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Has a diagnosis of mild to moderate, symptomatic, single-level degenerative disc disease (DDD) from L3-S1.
2. Has a target disc that meets Modified Pfirrmann Grade 3-7.
3. Is ≥18 and ≤75 years of age, skeletally mature, and has a body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2 at Screening.
4. Has been experiencing chronic low back pain for at least 6 months prior to Screening.
5. Has had low back pain that is unresponsive to at least 3 months of conservative care (nonoperative treatment) to include at least one non-pharmacological intervention which may include physical therapy, acupuncture, chiropractic manipulation, massage, and at home medically supervised exercise program and two pharmacological interventions which may include NSAIDs, acetaminophen, duloxetine, and/or injectable therapy.
6. Has pre-treatment low back pain score of 45 to 90 on VAS (Visual Analogue Scale) for low back pain at Screening and Day 1.
7. Has pre-treatment ODI score of 35 to 90 at Screening and Day 1.
8. Is willing to voluntarily sign the informed consent form and agrees to the release of previous medical history for purposes of this study (i.e., HIPAA authorization) at Screening.
9. Is physically and mentally able to comply with the protocol, able to understand and complete the required forms, and willing and able to adhere to the requirements of the protocol in the opinion of the Investigator.
10. Female-born subjects of childbearing potential must agree to and comply with using highly effective methods of birth control for the duration of the study (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, condoms, or a vasectomized partner).-
2. Has a target disc that meets Modified Pfirrmann Grade 3-7.
3. Is ≥18 and ≤75 years of age, skeletally mature, and has a body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2 at Screening.
4. Has been experiencing chronic low back pain for at least 6 months prior to Screening.
5. Has had low back pain that is unresponsive to at least 3 months of conservative care (nonoperative treatment) to include at least one non-pharmacological intervention which may include physical therapy, acupuncture, chiropractic manipulation, massage, and at home medically supervised exercise program and two pharmacological interventions which may include NSAIDs, acetaminophen, duloxetine, and/or injectable therapy.
6. Has pre-treatment low back pain score of 45 to 90 on VAS (Visual Analogue Scale) for low back pain at Screening and Day 1.
7. Has pre-treatment ODI score of 35 to 90 at Screening and Day 1.
8. Is willing to voluntarily sign the informed consent form and agrees to the release of previous medical history for purposes of this study (i.e., HIPAA authorization) at Screening.
9. Is physically and mentally able to comply with the protocol, able to understand and complete the required forms, and willing and able to adhere to the requirements of the protocol in the opinion of the Investigator.
10. Female-born subjects of childbearing potential must agree to and comply with using highly effective methods of birth control for the duration of the study (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, condoms, or a vasectomized partner).-
Exclusion Criteria
11. Has low back pain that in the Investigator's opinion is predominately myofascial in nature.
12. Has constant, unchanging low back pain that is not improved in any spinal position.
13. Has radiculopathy resulting from nerve compression.
14. Has non-radicular unilateral or bilateral leg pain with intensity greater than 50% of the intensity of the low-back pain, as measured by VAS.
15. Leg pain that is of radicular origin, i.e., due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.
16. Has frequent leg pain that extends below the knee.
17. Has severe unilateral or bilateral osteoarthritis of the knee or hip.
18. Severe spinal arthritis
19. Has cauda equina syndrome.
20. Has had previous lumbar spine surgery.
21. Has had previous disc invasive treatment procedures (i.e., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) or intradiscal injections (i.e., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate) or diagnostic discography at L3-S1 within the 3 months prior to Screening.
22. Subjects who have had basivertebral nerve ablation at L3-S1.
23. Has clinical suspicion of facet pain as the primary pain generator.
24. Has current infection at the planned procedure site, active systemic infection, or current or prior history of lumbar spinal infection (i.e., discitis, septic arthritis, epidural abscess).
25. Has a history of fibromyalgia.
26. Has tested positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV).
27. Has presence of an active malignancy or tumor, or a prior history of malignancy within the last five years (except for basal cell carcinoma of the skin).
28. Has presence or prior history of a spinal malignancy.
29. Has significant systemic disease, such as unstable angina or autoimmune disease, such as rheumatoid arthritis. Has a history of congenital or acquired coagulopathy or thrombocytopenia.
31\. Is currently taking anticoagulant, antiplatelet, or thrombolytic medications (except for aspirin or nonsteroidal anti-inflammatory drugs \[NSAIDS\]) and at the Investigator's medical discernment and discretion is unable to withhold medications for the time required per site standard or care, prior to the IDCT injection or is taking antineoplastic medications.
32\. Is at higher risk for post-surgical infection (e.g., taking immunosuppressants), has a severe infection or a history of serious infection.
33\. Has concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days before Screening.
34\. Is taking opioids greater than 20 MME per day on an intermittent (as needed) basis OR is taking 20 MME or greater daily for more than 3 months prior to Screening
35\. Has a history of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.
36\. Has a history of hypersensitivity or anaphylactic reaction to bovine products, sodium hyaluronate/ hyaluronan/ hyaluronic acid, gentamicin, amphotericin b, dimethyl sulfoxide (DMSO), crustaceous/ shellfish, or porcine products.
37\. Has an uncontrolled psychiatric condition or substance/alcohol abuse that would potentially interfere with the subject's participation in the study within 2 years prior to Screening in the opinion of the Investigator.
38\. Has positive serum pregnancy test or nursing at time of Screening or has plans to become pregnant within the planned length of the study (2 years).
39\. Has a body habitus that precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible.
40\. Has or requires an implantable electronic defibrillator, pacemaker, or has other contraindication to MRI scanning or cannot tolerate MRI scanning. Subjects who are expected to require a defibrillator or pacemaker, as determined by the Investigator should be excluded.
41\. Has participated in another clinical study within the 6 months prior to Screening.
42\. Has been a recipient or plans to be a recipient during trial participation of stem cell product to treat the lumbar spine.
43\. Has participated in a prior IDCT clinical study.
44\. Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage.
45\. A person who would not be available for the entire planned length of the trial.
46\. Has active or pending worker's compensation claims. 47. In the Investigators opinion, the subject is not suitable for participation in the clinical trial.
48\. Two or more discs (L3-S1) that have a Modified Pfirrmann Grade 3-7.
49\. Has evidence of prior lumbar vertebral body fracture at L3-S1.
50\. Has scoliosis with curvature \> 10 degrees.
51\. Has congenital spinal irregularities such as segmentation.
52\. Has an acute fracture of the spine at the time of enrollment in the study. Clinically compromised vertebral bodies within L3-S1 due to current or past trauma, e.g., sustained pathological fracture or multiple fractures of vertebrae.
53\. Has evidence of dynamic instability on lumbar flexion extension per screening radiographs as indicated by \>4.5 mm of translational motion at L3-S1; \>15° of angular motion at L3/-L4; \>20° of angular motion at L4-L/5; or \>25° angular motion at L5/-S1.
54\. Has Grade 2 or higher spondylolisthesis at L3-S1, as assessed by Meyerding classification.
55\. Has lumbar spondylitis or other undifferentiated spondyloarthropathy.
56\. Has Modic Type III Changes at L3-S1.
57\. Has radiographic evidence or suspicion of a full thickness annular tear at L3-S1.
58\. Has evidence of abnormal disc morphology defined as an extrusion or sequestration according to Fardon classification at L3- S1.
59\. Has herniation \> 3 mm in AP dimension that is associated with nerve root compression.
12. Has constant, unchanging low back pain that is not improved in any spinal position.
13. Has radiculopathy resulting from nerve compression.
14. Has non-radicular unilateral or bilateral leg pain with intensity greater than 50% of the intensity of the low-back pain, as measured by VAS.
15. Leg pain that is of radicular origin, i.e., due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.
16. Has frequent leg pain that extends below the knee.
17. Has severe unilateral or bilateral osteoarthritis of the knee or hip.
18. Severe spinal arthritis
19. Has cauda equina syndrome.
20. Has had previous lumbar spine surgery.
21. Has had previous disc invasive treatment procedures (i.e., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) or intradiscal injections (i.e., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate) or diagnostic discography at L3-S1 within the 3 months prior to Screening.
22. Subjects who have had basivertebral nerve ablation at L3-S1.
23. Has clinical suspicion of facet pain as the primary pain generator.
24. Has current infection at the planned procedure site, active systemic infection, or current or prior history of lumbar spinal infection (i.e., discitis, septic arthritis, epidural abscess).
25. Has a history of fibromyalgia.
26. Has tested positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV).
27. Has presence of an active malignancy or tumor, or a prior history of malignancy within the last five years (except for basal cell carcinoma of the skin).
28. Has presence or prior history of a spinal malignancy.
29. Has significant systemic disease, such as unstable angina or autoimmune disease, such as rheumatoid arthritis. Has a history of congenital or acquired coagulopathy or thrombocytopenia.
31\. Is currently taking anticoagulant, antiplatelet, or thrombolytic medications (except for aspirin or nonsteroidal anti-inflammatory drugs \[NSAIDS\]) and at the Investigator's medical discernment and discretion is unable to withhold medications for the time required per site standard or care, prior to the IDCT injection or is taking antineoplastic medications.
32\. Is at higher risk for post-surgical infection (e.g., taking immunosuppressants), has a severe infection or a history of serious infection.
33\. Has concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days before Screening.
34\. Is taking opioids greater than 20 MME per day on an intermittent (as needed) basis OR is taking 20 MME or greater daily for more than 3 months prior to Screening
35\. Has a history of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.
36\. Has a history of hypersensitivity or anaphylactic reaction to bovine products, sodium hyaluronate/ hyaluronan/ hyaluronic acid, gentamicin, amphotericin b, dimethyl sulfoxide (DMSO), crustaceous/ shellfish, or porcine products.
37\. Has an uncontrolled psychiatric condition or substance/alcohol abuse that would potentially interfere with the subject's participation in the study within 2 years prior to Screening in the opinion of the Investigator.
38\. Has positive serum pregnancy test or nursing at time of Screening or has plans to become pregnant within the planned length of the study (2 years).
39\. Has a body habitus that precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible.
40\. Has or requires an implantable electronic defibrillator, pacemaker, or has other contraindication to MRI scanning or cannot tolerate MRI scanning. Subjects who are expected to require a defibrillator or pacemaker, as determined by the Investigator should be excluded.
41\. Has participated in another clinical study within the 6 months prior to Screening.
42\. Has been a recipient or plans to be a recipient during trial participation of stem cell product to treat the lumbar spine.
43\. Has participated in a prior IDCT clinical study.
44\. Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage.
45\. A person who would not be available for the entire planned length of the trial.
46\. Has active or pending worker's compensation claims. 47. In the Investigators opinion, the subject is not suitable for participation in the clinical trial.
48\. Two or more discs (L3-S1) that have a Modified Pfirrmann Grade 3-7.
49\. Has evidence of prior lumbar vertebral body fracture at L3-S1.
50\. Has scoliosis with curvature \> 10 degrees.
51\. Has congenital spinal irregularities such as segmentation.
52\. Has an acute fracture of the spine at the time of enrollment in the study. Clinically compromised vertebral bodies within L3-S1 due to current or past trauma, e.g., sustained pathological fracture or multiple fractures of vertebrae.
53\. Has evidence of dynamic instability on lumbar flexion extension per screening radiographs as indicated by \>4.5 mm of translational motion at L3-S1; \>15° of angular motion at L3/-L4; \>20° of angular motion at L4-L/5; or \>25° angular motion at L5/-S1.
54\. Has Grade 2 or higher spondylolisthesis at L3-S1, as assessed by Meyerding classification.
55\. Has lumbar spondylitis or other undifferentiated spondyloarthropathy.
56\. Has Modic Type III Changes at L3-S1.
57\. Has radiographic evidence or suspicion of a full thickness annular tear at L3-S1.
58\. Has evidence of abnormal disc morphology defined as an extrusion or sequestration according to Fardon classification at L3- S1.
59\. Has herniation \> 3 mm in AP dimension that is associated with nerve root compression.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DiscGenics, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Flood
Role: STUDY_DIRECTOR
DiscGenics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Axis Spine Center
Post Falls, Idaho, United States
Site Status
RECRUITING
The Orthopedic Center of St. Louis
St Louis, Missouri, United States
Site Status
RECRUITING
Carolinas Pain Institute/ Center For Clinical Research
Winston-Salem, North Carolina, United States
Site Status
RECRUITING
Semmes Murphey Neurological Clinic
Memphis, Tennessee, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Role: backup
901-259-5319
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DGX-A02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive
NCT03737461
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Non-surgical Spinal Decompression Therapy and Outcomes
NCT06525896
RECRUITING
NA
Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease
NCT03692221
WITHDRAWN
EARLY_PHASE1
Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain
NCT01263054
COMPLETED
NA
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
NCT01290367
COMPLETED
PHASE2
Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease
NCT06144970
NOT_YET_RECRUITING
PHASE1
Trial for Treating Painful Degenerative Disc Disease
NCT05287867
RECRUITING
NA
Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD
NCT04759105
COMPLETED
PHASE2
Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease
NCT03461458
TERMINATED
PHASE1
A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration
NCT01124006
COMPLETED
PHASE2
Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration
NCT02338271
UNKNOWN
PHASE1
A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration
NCT01158924
COMPLETED
PHASE1/PHASE2
Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine
NCT02529566
UNKNOWN
Stem Cells vs. Steroids for Discogenic Back Pain
NCT04735185
WITHDRAWN
NA
Isolation and Authentication of Mesenchymal Stem Cell-like Progenitor Cells From the Degenerated Intervertebral Disc of Lumbar Spine
NCT01213953
UNKNOWN
Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease
NCT01513694
COMPLETED
PHASE1/PHASE2
A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration
NCT01182337
COMPLETED
PHASE1/PHASE2
A Pivotal Study of rhBMP-2/ACS/INTER FIX™ Device for Posterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
NCT01491464
TERMINATED
NA
Correlation Between RMI of Degenerative Disk Disease and Reduction of Pain After Disk-infiltration Treatments
NCT04142580
COMPLETED
A Trial of Corticosteroids for Low Back Pain
NCT00290589
COMPLETED
PHASE3
Epidural Steroid Following Discectomy for Herniated Disc Reduces Morbidity
NCT01499641
COMPLETED
NA
Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration
NCT02379689
UNKNOWN
NA
Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy
NCT01850771
TERMINATED
NA
Post-Approval Study Protocol for the Simplify Cervical Artificial Disc
NCT04630626
COMPLETED
NA
CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
NCT07137559
AVAILABLE